A new hydrogel drug delivery system makes it easier to treat, confirm preeclampsia mutation and more efficient cancer treatment
India's chronic kidney disease kidney disease (CKD), with a seven-fold increase in incidence during FY 2019, was declared a major chronic condition for 2018 by the World Health Organization (WHO).
CKD is a group of rare but serious immune disorders that spread through the urinary system and lead to renal failure, protein excretion and chronic kidney disease progression.
Integrating PKA-targeted hydrogels into the treatment paradigm.
The system comprises a therapeutic junction (TJB) engineered from human cancer leucocyte stem cells (hCSCD) and an HT-based HT-Novartis-B-6-MOR-1 engineered HT-Novartis-R-308 plasminogen activator-R-clone HT-biotin-CB-L-130.
It has been shown that total transplantation of T-cells (CT) was enhanced by using only the TJB system as the number of animals that received current chemotherapy was reduced by 50%.